Despite the inter-patient variation, some of the mutations have developed independent expression and prognostic value such as the splicing factor 3 subunit 1 (SF3B1) mutation with ring sideroblasts (RS) (25) in 60%-80% of RS-MDS (26) and the association of tet methylcytosine deoxygenase 2 (TET2) mutation with longer OS, good prognosis (27), phenotype of the disease (28), and an increased response to 5-AZA (29, 30). Here, SF3B1 is linked to myelodysplastic syndrome.